When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
BFRA - Is Biofrontera Stock A Buy Or Sell? Several Catalysts In 2022
Biofrontera AG
Biofrontera is eyeing significant growth opportunities for its FDA-approved skin disease photodynamic therapy drug "Ameluz".
Updates regarding several ongoing clinical studies for expanded label indications can be a catalyst for the stock in 2022.
While Biofrontera maintains a positive long-term outlook, we expect the stock to remain highly volatile following what appears to be a speculative momentum-based rally in recent weeks.